Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposome bupivacaine vs bupivacaine hydrochloride adductor canal block for postoperative analgesia in unicompartmental knee arthroplasty in elderly patients
ChiCTR2400091553Phase 4Not yet recruiting
- Sponsor
- Wuhan Tongji Modern Pharmaceutical Technology
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bupivacaine in knee osteoarthritis (OA) (2 arms), sponsored by Wuhan Tongji Modern Pharmaceutical Technology. Primary endpoint: Pain intensity (NRS). Planned start Jul 2024; status: not yet recruiting.
02
Drugs
bupivacaine
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on ChiCTR2400091553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091553.